好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Factors Associated with Phobic and Obsessive Compulsive Symptoms in Epilepsy
Epilepsy
P03 - (-)
136
BACKGROUND: Although generalized anxiety symptoms are a major determinant of quality of life in epilepsy, little is known about other anxiety types, including phobic and obsessive compulsive symptoms.
DESIGN/METHODS: Adult patients who underwent neuropsychological evaluation at the Columbia Comprehensive Epilepsy Center from 1999-2012 completed the Symptom Checklist 90-R (SCL-90-R), a validated self-report psychiatric symptom index with phobic and obsessive compulsive subscales. The cohort was divided into two obsessive compulsive symptom groups (n=382): high obsessive compulsive symptoms (SCL-90-R obsessive compulsive T score >=60), and lower obsessive compulsive symptoms (obsessive compulsive T score <60). Chi square and two-sample t tests were used to test the association of obsessive compulsive symptom group with demographic and epilepsy related factors. A separate, similar analysis was carried out by dividing the cohort (n=379) into high and lower phobic symptom groups (SCL-90-R phobic T score >=60 and <60, respectively).
RESULTS: The prevalence of high obsessive compulsive symptoms was 69% (mean T score 64), whereas the prevalence of high phobic symptoms was 36% (mean T score 56). Phobic symptoms were associated with race (p=0.003, more nonwhites in high phobic group), education (mean 1.3 fewer years of education in high phobic group, p=0.000), and number of antiepileptic drugs (p=0.007, greater prevalence of high phobic symptoms with polytherapy). There was no association of phobic symptom group with gender, age, epilepsy onset age, seizure frequency, epilepsy causing lesion, generalized vs. focal epilepsy, lateralization or localization in focal epilepsy, or mesial vs. lateral focus in temporal lobe epilepsy. There were no significant associations between high obsessive compulsive symptoms and any epilepsy related or demographic factors.
CONCLUSIONS: Epilepsy patients who are nonwhite, have lower education, and receive AED polytherapy may be at increased risk for phobic symptoms.
Authors/Disclosures
Heidi Munger Clary, MD, MPH (Wake Forest University School of Medicine)
PRESENTER 		Dr. Munger Clary has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Xenon. Dr. Munger Clary has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Prova 好色先生. Dr. Munger Clary has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia Open. Dr. Munger Clary has stock in HCA Healthcare. Dr. Munger Clary has stock in Eli Lilly. Dr. Munger Clary has stock in Procter and Gamble. Dr. Munger Clary has stock in CVS. Dr. Munger Clary has stock in Johnson and Johnson. Dr. Munger Clary has stock in Novartis. Dr. Munger Clary has stock in Danahauer. The institution of Dr. Munger Clary has received research support from National Institute of Health. The institution of Dr. Munger Clary has received research support from Suzanne Marcus Collins Foundation. The institution of Dr. Munger Clary has received research support from Eysz, Inc. The institution of Dr. Munger Clary has received research support from Department of Defense. The institution of Dr. Munger Clary has received research support from Duke Endowment. Dr. Munger Clary has received personal compensation in the range of $500-$4,999 for serving as a speaker, Psychiatry Commission member with International League Against Epilepsy. Dr. Munger Clary has received personal compensation in the range of $0-$499 for serving as a Faculty with J. Kiffin Penry Epilepsy 好色先生 Programs. Dr. Munger Clary has a non-compensated relationship as a advisor, potential site PI with Liva Nova that is relevant to AAN interests or activities.
No disclosure on file
Roy L. Freeman, MD (Beth Israel Deaconess Hosp) Dr. Freeman has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Cutaneous Diagnostic Life Sciences. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vertex. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Theravance. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Inhibikase. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. Freeman has received research support from NIH. The institution of Dr. Freeman has received research support from Theravance. The institution of Dr. Freeman has received research support from Biohaven. The institution of Dr. Freeman has received research support from Lundbeck. Dr. Freeman has received research support from Regeneron.